GSK steps up to support new FDI project on partially dentate patients

04 February 2019 Edentulism

FDI is building on its existing relationship with GlaxoSmithKline (GSK) to include a collaboration on the management of partially dentate patients, or patients who have one or more missing teeth.

"Supporting FDI to increase global awareness about the challenges to treatment and care of partially dentate patients in the 2020s is a chance for us to further our inclusive, people-centered approach to oral care. We look forward to the outcomes of this initiative by FDI to further help advance oral health outcomes for all patients."
DR ROSHAN VARGHESE, MEDICAL AFFAIRS DIRECTOR

GSK is a valued and long-standing FDI partner and continues to support the Global Periodontal Health Project, the Oral Health Observatory and FDI’s advocacy work on oral health.

"We are so pleased that GSK has offered their full backing to improve health outcomes for partially dentate patients. It is essential to consider the specific needs of all patients, and we are thrilled to have GSK behind us as we embark on this new project. A big thanks to GSK for their continued confidence in our vision."
DR KATHRYN KELL, FDI PRESIDENT

The Partially Dentate Patients Project

The Partially Dentate Patients (PDP) Project aims to empower oral health professionals to understand and support the needs of their patients, improve their health outcomes, and increase global awareness about their treatment options and specific needs.

Caring for a partially dentate patient is a long-term process that includes three main pillars: a pre-treatment/assessment phase, a treatment phase, and a post-treatment/long-term care phase. The PDP Project encourages dentists to place equal importance on each of these three phases and to organize their treatment and care plan along this continuum.

FDI will produce a white paper and a chairside guide on the topic that will be released during the ADA CERP-certified PDP symposium at the FDI World Dental Congress in San Francisco, California, in September 2019. The symposium will be led by two of the three PDP project experts: Dr William Cheung, an FDI Education Committee member and an honorary associate professor at the University of Hong Kong and Prof. Finbarr Allen, a professor of operative dentistry, endodontics and prosthodontics and the dean of the Faculty of Dentistry at the National University of Singapore. The third PDP project expert is Prof. Angus Walls, a professor of restorative dentistry and the director of the Edinburgh Dental Institute and the past-president of the International Association for Dental Research.

About GlaxoSmithKline

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK aims to bring differentiated, high-quality and needed healthcare products to as many people as possible, with three global businesses, scientific and technical know-how and talented people.

Share it